Puma Biotechnology Inc (NASDAQ:PBYI) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $40.45 and last traded at $41.70, with a volume of 12587 shares changing hands. The stock had previously closed at $41.90.

PBYI has been the subject of a number of analyst reports. BidaskClub lowered Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, July 28th. JPMorgan Chase & Co. boosted their price objective on Puma Biotechnology from $80.00 to $83.00 and gave the company a “buy” rating in a research report on Friday, August 10th. Citigroup boosted their price objective on Puma Biotechnology from $146.00 to $164.00 and gave the company a “buy” rating in a research report on Thursday, June 28th. Stifel Nicolaus reduced their price objective on Puma Biotechnology from $95.00 to $87.00 and set a “buy” rating for the company in a research report on Friday, May 11th. Finally, Credit Suisse Group set a $106.00 price objective on Puma Biotechnology and gave the company a “buy” rating in a research report on Thursday, April 26th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. Puma Biotechnology has an average rating of “Hold” and a consensus price target of $101.40.

The stock has a market cap of $1.70 billion, a PE ratio of -5.24 and a beta of -0.10. The company has a debt-to-equity ratio of 3.14, a current ratio of 2.68 and a quick ratio of 2.64.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.26) by $0.09. Puma Biotechnology had a negative return on equity of 367.92% and a negative net margin of 146.27%. The company had revenue of $50.80 million during the quarter, compared to analyst estimates of $45.67 million. During the same quarter in the previous year, the firm posted ($1.38) EPS. research analysts forecast that Puma Biotechnology Inc will post -3.68 earnings per share for the current year.

In other Puma Biotechnology news, insider Charles R. Eyler sold 1,211 shares of the business’s stock in a transaction on Friday, June 1st. The stock was sold at an average price of $53.00, for a total transaction of $64,183.00. Following the completion of the transaction, the insider now owns 35,816 shares in the company, valued at approximately $1,898,248. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Alan H. Auerbach sold 12,520 shares of the business’s stock in a transaction on Friday, July 20th. The stock was sold at an average price of $52.00, for a total value of $651,040.00. Following the transaction, the chief executive officer now owns 4,179,061 shares of the company’s stock, valued at approximately $217,311,172. The disclosure for this sale can be found here. Insiders have sold a total of 15,567 shares of company stock valued at $810,603 in the last quarter. 21.50% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the business. State of Wisconsin Investment Board lifted its holdings in shares of Puma Biotechnology by 3.8% in the second quarter. State of Wisconsin Investment Board now owns 29,700 shares of the biopharmaceutical company’s stock valued at $1,757,000 after buying an additional 1,100 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Puma Biotechnology by 307.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,547 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,167 shares during the period. Creative Planning lifted its holdings in shares of Puma Biotechnology by 30.1% in the second quarter. Creative Planning now owns 5,129 shares of the biopharmaceutical company’s stock valued at $303,000 after buying an additional 1,188 shares during the period. Swiss National Bank lifted its holdings in shares of Puma Biotechnology by 2.4% in the first quarter. Swiss National Bank now owns 51,930 shares of the biopharmaceutical company’s stock valued at $3,534,000 after buying an additional 1,200 shares during the period. Finally, Xact Kapitalforvaltning AB lifted its holdings in shares of Puma Biotechnology by 50.7% in the first quarter. Xact Kapitalforvaltning AB now owns 4,458 shares of the biopharmaceutical company’s stock valued at $303,000 after buying an additional 1,500 shares during the period. Institutional investors own 92.44% of the company’s stock.

Puma Biotechnology Company Profile (NASDAQ:PBYI)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Featured Story: How to Track your Portfolio in Google Finance

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.